An analysis of the benefits of SGLT2 inhibitors in the progression of chronic kidney disease beyond type 2 diabetes. Acervo Médico [Internet]. 2024 Aug. 25 [cited 2026 Nov. 3];24:e16309. Available from: https://acervomais.com.br/medico/article/view/16309